ADC THERAPEUTICS
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
ADC THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Therapeutics
Founded:
2011-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.adctherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 908-731-5556
Total Funding:
691.55 M USD
Technology used in webpage:
Nginx Microsoft Exchange Online Amazon ReCAPTCHA Cloudflare Person Schema Cloudflare Hosting Gravatar Profiles Apple Mobile Web App Capable Cloudflare SSL
Current Advisors List
Board_member
2012-03-01
Board_member
2012-03-01
Board_member
Board_member
2012-03-01
Board_member
2012-03-01
Board_member
2020-03-01
Board_member
2022-05-01
Current Employees Featured
Liangyi Zhang Associate Director, CMC Analytical @ ADC Therapeutics
Associate Director, CMC Analytical
2017-05-01
Michael Forer Vice Chairman and Executive Vice President @ ADC Therapeutics
Vice Chairman and Executive Vice President
Jens Würthner Head of Clinical Development – EU @ ADC Therapeutics
Head of Clinical Development – EU
Jay Feingold Senior Vice President, Chief Medical Officer & Head of Oncology Clinical Development @ ADC Therapeutics
Senior Vice President, Chief Medical Officer & Head of Oncology Clinical Development
Kimberly Pope Chief Human Resources Officer @ ADC Therapeutics
Chief Human Resources Officer
2020-08-01
Ameet Mallik President & CEO @ ADC Therapeutics
President & CEO
2022-05-01
David Gilman Chief Business & Strategy Officer @ ADC Therapeutics
Chief Business & Strategy Officer
2022-01-01
Victor Sandor Independent Director @ ADC Therapeutics
Independent Director
2020-04-01
Oscar Segurado Chief Medical Officer @ ADC Therapeutics
Chief Medical Officer
2019-12-01
Susan Romanus Chief Compliance Officer @ ADC Therapeutics
Chief Compliance Officer
2018-06-01
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Post-IPO Debt - ADC Therapeutics
Deerfield
Deerfield investment in Post-IPO Debt - ADC Therapeutics
Redmile Group
Redmile Group investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series E - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series E - ADC Therapeutics
Redmile Group
Redmile Group investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series E - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series D - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series D - ADC Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-13 | ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer |
| 2022-05-09 | ADC Therapeutics Announces CEO Transition |
| 2020-04-21 | ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer |
Official Site Inspections
http://www.adctherapeutics.com Semrush global rank: 2.17 M Semrush visits lastest month: 9.11 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ADC Therapeutics"
Antibody Drug Conjugates Cancer Treatment – ADC Therapeutics
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update March 27, 2025; ADC Therapeutics Announces Abstracts Accepted for …See details»
ADC Therapeutics - Crunchbase Company Profile
Contact Email info@adctherapeutics.com Phone Number +1 908-731-5556 ADC Therapeutics is a clinical-stage oncology drug discovery and development …See details»
Investors - ADC Therapeutics
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs). Learn more about …See details»
ADC Therapeutics - LinkedIn
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer.See details»
ADC Therapeutics Company Profile | Management and Employees …
John@adctherapeutics.com: 5: last: Smith@adctherapeutics.com: Your Questions, Our Answers Get Free Access to ADC Therapeutics Contacts Info. What is ADC Therapeutics revenue? …See details»
ADC Therapeutics - Craft
Oct 29, 2024 ADC Therapeutics has 5 employees across 3 locations and $69.56 m in annual revenue in FY 2023. See insights on ADC Therapeutics including office locations, competitors, …See details»
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 …
3 days ago The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. A live webcast of the call will be available under "Events & Presentations" in the …See details»
ADC Therapeutics Announces Abstracts Accepted for Presentation …
5 days ago ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple …See details»
ADC Therapeutics Announces Abstracts Accepted for Presentation …
4 days ago ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple …See details»
Contact Us - ADC Therapeutics
Report Adverse Reactions or Product Complaints. To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You ...See details»
Medical Information Hub | ADC Therapeutics | HCP Site
You are now leaving the ADC Therapeutics Medical Information Hub. ADC Therapeutics does not necessarily endorse the organization associated with this link and takes no responsibility for …See details»
ADC Therapeutics Makes Grants to New Employees Under …
Dec 2, 2024 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company …See details»
ADC Therapeutics Reports Fourth Quarter and Full Year 2024
1 day ago A live webcast of the call will be available under “Events & Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived …See details»
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 …
2 days ago A live webcast of the call will be available under "Events & Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived …See details»
ADC Therapeutics Announces CEO Transition
May 9, 2022 Eugenia.Litz@adctherapeutics.com +44 7879 627205 Amanda Hamilton ADC Therapeutics amanda.hamilton@adctherapeutics.com +1 917-288-7023 USA Media Mary Ann …See details»
Careers - ADC Therapeutics
Attention: Search firms/Third-party recruitment agencies. The People team manages the recruiting for all positions at ADC Therapeutics. We will only accept résumés from a search …See details»
ADC Therapeutics Announces Abstracts Accepted for Presentation …
4 days ago /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...See details»
Our Technology - ADC Therapeutics
A novel class of PBD dimers. ADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel …See details»
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
Dec 19, 2022 ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve …See details»
Antibody Drug Conjugates Clinical Development - ADC Therapeutics
ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD–dimer toxin. Once bound to a CD22-expressing cell, ADCT-602 is internalized into the …See details»